Prometheus Biosciences, Inc. (RXDX) |
|
116.12 1.65 (1.44%)
|
01-27 16:00 |
|
Open: |
114.58 |
Pre. Close: |
114.47 |
|
High:
|
117.43 |
Low:
|
113.12 |
|
Volume:
|
221,514 |
Market Cap:
|
5,398(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:47:42 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 143.37 One year: 167.45 |
| Support: |
Support1: 110.74 Support2: 103.33 |
| Resistance: |
Resistance1: 122.75 Resistance2: 143.37 |
| Pivot: |
115.81  |
| Moving Average: |
MA(5): 117.06 MA(20): 113.54
MA(100): 71.91 MA(250): 50.53 |
| MACD: |
MACD(12,26): 6.3  Signal(9): 7.9 |
| Stochastic oscillator: |
%K(14,3): 68.1 %D(3): 73.1 |
| RSI: |
RSI(14): 60.8 |
| 52-week: |
High: 122.75 Low: 21.5 |
| Average Vol(K): |
3-Month: 911 (K) 10-Days: 416 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RXDX ] has closed below upper band by 48.3%. Bollinger Bands are 32.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
117.49 - 118.07 |
118.07 - 118.65 |
|
Low:
|
111.78 - 112.37 |
112.37 - 112.97 |
|
Close:
|
115.16 - 116.11 |
116.11 - 117.07 |
|
Company Description |
|
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. |
Headline News |
Mon, 16 Jan 2023
Zacks Investment Ideas feature highlights: XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB - Yahoo Finance
Fri, 13 Jan 2023
Biotech's Blockbuster Week: 3 Stocks to Watch - Yahoo Finance
Tue, 10 Jan 2023
Wall Street Analysts Believe Prometheus Biosciences, Inc. (RXDX) Could Rally 26.51%: Here's is How to Trade - Yahoo Finance
Fri, 09 Dec 2022
Prometheus (NASDAQ:RXDX) Stock: Here's What Caused the ... - TipRanks
Thu, 08 Dec 2022
Prometheus Biosciences A Buy On Positive Phase 2 Data (NASDAQ ... - Seeking Alpha
Wed, 07 Dec 2022
Hot Stocks: CVNA crashes more than 40%; ASO jumps on earnings ... - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
46 (M) |
|
% Held by Insiders
|
2.896e+007 (%) |
|
% Held by Institutions
|
19.1 (%) |
|
Shares Short
|
4,890 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.2739e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
778 |
|
Return on Equity (ttm)
|
-27.3 |
|
Qtrly Rev. Growth
|
7.19e+006 |
|
Gross Profit (p.s.)
|
-0.47 |
|
Sales Per Share
|
0.06 |
|
EBITDA (p.s.)
|
-1.54 |
|
Qtrly Earnings Growth
|
-2.8 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-104 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
1766.29 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
3.43e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
